Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565886 | 0.89 | KDM4E (0.59) | HSD17B3CYP2C9ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3565889 | 0.89 | KDM4E (0.59) | HSD17B3CYP2C9ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10509072 | 0.82 | TTR (0.53) | ALDH1A1MAPTSMN1; SMN2KDM4EAKR1B10 | |
| SCHEMBL10509071 | 0.82 | TTR (0.53) | ALDH1A1MAPTSMN1; SMN2KDM4EAKR1B10 | |
| SCHEMBL31380271 | 0.82 | TTR (0.53) | ALDH1A1MAPTSMN1; SMN2KDM4EAKR1B10 | |
| SCHEMBL4089747 | 0.80 | TTR (0.57) | ALDH1A1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL4089749 | 0.80 | TTR (0.57) | ALDH1A1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL18197883 | 0.79 | ALDH1A1 (0.39) | HSD17B3ALDH1A1KDM4EPKMNPSR1 | |
| SCHEMBL17500232 | 0.79 | NR1H4 (0.51) | ALDH1A1SMN1; SMN2LMNAKDM4EPKM | |
| SCHEMBL17500223 | 0.79 | NR1H4 (0.51) | ALDH1A1SMN1; SMN2LMNAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012024282-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | SHIH CHARLES C-Y (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | PDCD5, IL5, MALT1 | HSD17B3 695/4885CYP1A2 1314/4885CYP2C9 1983/4885 |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | PHOSPHO1, SELENOI, CD2 | HSD17B3 2566/4885CYP1A2 4445/4885CYP2C9 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.